Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma

Max Gelman

Senior Editor

The multiple myeloma rivalry between Sanofi and J&J continued Wednesday evening, with the French drugmaker’s Sarclisa taking home a new approval in the indication. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma

Max Gelman

Senior Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump says he'll sign order on 'most-favored nation' drug price plans Monday

Revolution’s KRAS drugs appear competitive in several lung cancer settings

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Sanofi keeps nip­ping at J&J's heels as Sar­clisa notch­es new FDA ap­proval in mul­ti­ple myelo­ma

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma